BCR and B-cell chronic lymphocytic leukemia: Since the R110G mutation was first described in the context of autonomous signaling in subset 2 CLL, we tested to see if IGLV3-21R110G cases, which do not belong to subset 2, manifest ligand-independent autonomous activation of BCR.